Pfizer · NSE: PFIZER · BSE: 500680
Q4 FY25 results · Jan–Mar 2025
Pfizer reported revenue from operations of ₹591.91 crore (up 8.3% from Q4 FY24) and net profit of ₹330.94 crore (up 85.0% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a standalone basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 591.91 | 546.63 | +8.3% | 537.99 | +10.0% |
| Other income | 44.58 | 75.13 | −40.7% | 42.76 | +4.3% |
| Total income | 636.49 | 621.76 | +2.4% | 580.75 | +9.6% |
| Profit before tax | 425.80 | 243.86 | +74.6% | 172.44 | +146.9% |
| Net profit for the period | 330.94 | 178.86 | +85.0% | 127.60 | +159.4% |
| EPS, basic (₹) | 72.34 | 22.33 | +224.0% | 27.89 | +159.4% |
| Net margin (%) | 55.9 | 32.7 | 23.7 |
Standalone
- Filed with BSE
- 10 Jun 2025, 15:07 IST
- Board meeting
- 19 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE